PCI Biotech and Ultimovacs announced that they are initiating a preclinical research collaboration. The purpose of the collaboration is to utilise the companies' complementary scientific platforms to explore potential synergies. The partnership is governed by a preclinical research collaboration agreement.

In brief, the preclinical research collaboration will evaluate technology compatibility and synergy based on in vivo studies. The companies will evaluate results achieved from this research collaboration and then explore the potential for a further partnership.